Cav1.2 on Qube 384 – pharmacology, stability and CiPA


Application report


Melanie Schupp, Rasmus Jacobsen, Mads P G Korsgaard



The voltage-sensitive L-type Ca2+-channel (LTCC) CaV1.2 is widely expressed in vascular smooth muscle tissue and the heart muscle1-3. The opening of the channels leads to an increase of intracellular calcium, which acts as second messenger and thereby affects a variety of cellular processes4 including heart muscle contraction and neurotransmitter release. CaV1.2 is therefore an important target in e.g. safety pharmacology screening. The channels are known to require a large depolarization for their activation and once activated they display a long-lasting current flow, which typically can be blocked by low micromolar concentrations of e.g. dihydropyridines, phenylalkylamines and benzothiazepines5,6.
In this study, currents from CHO-hCaV1.2 were recorded on the high-throughput platform Qube 384 in multi-hole mode (10 patch holes per well) at both a customer’s site and at Sophion. Success rates, rundown, sealing properties and the pharmacological effects of two compounds were determined.

Go to journal

Get in Touch

We strive to provide the best for our customers, and we are always ready to help. Please let us know if you have a question for us.

Follow us